DENVER, Colo. (247marketnews.com) -- Silence Therapeutics (NASDAQ:SLN) is heading into a potentially decisive moment as investors await topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV). The company scheduled an August 10 conference call and webcast to discuss the results, putting its lead clinical program directly in the spotlight. With the Phase 2 study fully enrolled and topline data previously expected in the third quarter, the event represents a major potential inflection point for the clinical-stage biotech and its siRNA platform.
Divesiran is designed to silence TMPRSS6, a gene involved in regulating hepcidin, the body's master iron regulator. By increasing hepcidin activity and reducing iron availability to the bone marrow, the therapy is intended to reduce the excessive red blood-cell production associated with PV and potentially reduce patients' dependence on phlebotomies. The randomized, double-blind, placebo-controlled Phase 2 SANRECO study enrolled 48 phlebotomy-dependent patients, with the primary endpoint focused on maintaining hematocrit below 45% without phlebotomy between weeks 18 and 36.
The setup heading into the readout is notable because earlier data have already given investors something to watch. At the European Hematology Association 2026 Congress, Silence reported follow-up Phase 1 results showing that only five phlebotomies were required during active treatment among 21 patients, compared with 80 in the six months before treatment. Only four additional phlebotomies were reported during the 16-week post-treatment follow-up, while the company also reported improvements in PV-related symptoms and quality of life. No dose-limiting toxicities were observed in that Phase 1 analysis.
The Phase 2 data now have the potential to determine whether those earlier signals translate into controlled clinical evidence. Investors will likely focus heavily on hematocrit control, phlebotomy reduction, safety and the performance of the Q6W and Q12W dosing regimens. A convincing result could strengthen the case for divesiran as a differentiated treatment approach in PV and potentially elevate Silence's broader mRNAi GOLD platform. Conversely, as with any clinical-stage biotech, disappointing efficacy or safety results could materially change the investment thesis.
Adding to the anticipation, Silence's shares were reported up sharply in premarket trading ahead of the data call, illustrating just how much attention the market is placing on the catalyst. With the company moving from encouraging Phase 1 observations to a pivotal Phase 2 data moment, Silence Therapeutics is firmly on the biotech radar as investors wait to see whether divesiran can deliver the next big step in its development story.
Sources & Links
Silence Therapeutics Investor Relations — Company information, investor materials and corporate updates.
Silence Therapeutics — Divesiran Program — Divesiran mechanism and development program.
Silence Therapeutics — SANRECO Clinical Trial — Trial design and endpoints.
Silence Therapeutics — EHA 2026 Divesiran Data — Phase 1 follow-up data and Phase 2 timeline.
Silence Therapeutics — Phase 2 Enrollment Announcement — Details of the 48-patient Phase 2 SANRECO study.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.